Target intelligence / Profile preview

Acetylcholinesterase and butyrylcholinesterase (AChE and BChE)

Target
AChE and BChE
Molecular classification
Enzyme, Serine hydrolase, Carboxylesterase family
01

Overview

Acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) are closely related enzymes that catalyze the hydrolysis of acetylcholine and butyrylcholine, respectively, both belonging to the serine hydrolase and carboxylesterase enzyme superfamilies[3][5]. AChE is primarily found in neuromuscular junctions and cholinergic synapses, where it rapidly terminates synaptic transmission by hydrolyzing acetylcholine, thus ensuring precise control of neural signaling[3][1]. BChE, though structurally similar, is distributed more broadly in the body, with less defined endogenous roles but is important for hydrolysis and detoxification of a wider range of ester-containing drugs and toxins and acts as a backup for AChE[5][6]. Both enzymes are major targets in neurodegenerative disorder therapy, especially Alzheimer’s disease: their selective inhibition increases central acetylcholine, improving cognitive symptoms[2][4][6]. Irreversible poisoning of these enzymes is central to the action of nerve agents, pesticides, and some drugs. Plasma BChE is used as a biomarker in various disease states, and genetic polymorphisms in BChE significantly affect individual drug responses. Safety concerns primarily relate to systemic cholinergic excess and the fine balance required for effective yet safe enzyme inhibition. Both enzymes remain highly relevant for clinical pharmacology, toxicology, and neurological disease management[2][8][6].

Other names
Acetylcholine acetylhydrolase (AChE)Butyrylcholine esterase (BChE)CholinesterasesAcetylhydrolaseAcetylcholine-esteraseCholine esterase I (for AChE)Pseudocholinesterase (for BChE)
02

Mechanism of action

Competitive or non-competitive inhibition of the active site gorge—blockade of acetylcholine or butyrylcholine hydrolysis Covalent modification by carbamates or organophosphates leading to irreversible inhibition Donepezil, rivastigmine, and galantamine are reversible inhibitors increasing synaptic acetylcholine Some drugs are dual AChE/BChE inhibitors, while others are selective

03

Biological functions

Hydrolysis of acetylcholine (AChE primary)Hydrolysis of butyrylcholine (BChE primary)Termination of cholinergic synaptic transmissionModulation of neurotransmissionDetoxification of ester-containing drugs and toxins (especially BChE)Secondary modulation of protein activity and neurochemical pathways (including tau phosphorylation, amyloid cascade)Metabolism of drugs such as succinylcholine and bambuterol (BChE)
04

Disease associations

Neurodegenerative disease (notably Alzheimer’s disease)Cognitive and neuropsychiatric dysfunctionCardiovascular disease (biomarker relevance for BChE)Potentially type 2 diabetes mellitus (AChE and BChE are altered)Role in protein-energy malnutrition and obesity (BChE as marker)Cocaine toxicity (substrate for BChE)
05

Safety considerations

Cholinergic toxicity (salivation, muscle cramps, bradycardia, seizures) from excessive enzyme inhibitionHepatotoxicity (notably with tacrine)Peripheral vs. central selectivity challenges—unwanted peripheral cholinergic effects, arrhythmias, hypotensionIndividual variability in BChE leading to unexpected drug responses (e.g., prolonged apnea with succinylcholine)
06

Interacting drugs

Donepezil

6 more in the full profile.

07

Biomarkers

BChE plasma levels as a marker for liver function, cardiovascular risk, and malnutritionAChE and BChE levels/ratios in cerebrospinal fluid and plasma for Alzheimer’s disease monitoringBChE activity as a monitor for exposure/toxicity from insecticides and nerve agents

Beyond the preview

Go deeper on Acetylcholinesterase and butyrylcholinesterase (AChE and BChE).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Acetylcholinesterase and butyrylcholinesterase (AChE and BChE).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call